Method for treating obesity
View Patent ↗The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.
1. A method of treating obesity in a mammal comprising administering to a mammal in need of such treatment at least one compound that enhances the activity of norepinephrine and/or dopamine selected from the group consisting of bupropion, atomoxetine, and reboxetine, and at least one weight-loss promoting anticonvulsant wherein said anticonvulsant is of formula (III):
wherein R 1 is hydrogen or a halogen atom, R 2 and R 3 are the same or different and are each hydrogen or an alkyl having 1 to 3 carbon atoms, and one of X and Y is a carbon atom and another is a nitrogen atom, provided that the group —CH 2 SO 2 NR 2 R 3 is bonded to the carbon atom of either of X and Y, or an alkali metal salt thereof.
2. The method according to claim 1 wherein said anticonvulsant is zonisamide.
3. The method according to claim 1 wherein said compound that enhances the activity of norepinephrine and/or dopamine is bupropion.
4. The method according to claim 1 wherein said anticonvulsant and said compound that enhances the activity of norepinephrine and/or dopamine are administered separately.
5. The method according to claim 1 wherein said anticonvulsant and said compound that enhances the activity of norepinephrine and/or dopamine are administered concurrently.
6. A method of reducing the risk of hypertension, diabetes or dyslipidaemia in a mammal comprising administering to a mammal in need of such reduction at least one compound that enhances the activity of norepinephrine and/or dopamine selected from the group consisting of bupropion, atomoxetine, and reboxetine, and at least one weight-loss promoting anticonvulsant according to formula (III) in amounts such that said reduction is effected, where formula (III) is:
wherein R 1 is hydrogen or a halogen atom, R 2 and R 3 are the same or different and are each hydrogen or an alkyl having 1 to 3 carbon atoms, and one of X and Y is a carbon atom and another is a nitrogen atom, provided that the group —CH 2 SO 2 NR 2 R 3 is bonded to the carbon atom of either of X and Y, or an alkali metal salt thereof.
7. A composition comprising at least one compound that enhances the activity of norepinephrine and/or dopamine selected from the group consisting of bupropion, atomoxetine, and reboxetine, and at least one weight-loss promoting anticonvulsant of formula (III):
wherein R 1 is hydrogen or a halogen atom, R 2 and R 3 are the same or different and are each hydrogen or an alkyl having 1 to 3 carbon atoms, and one of X and Y is a carbon atom and another is a nitrogen atom, provided that the group —CH 2 SO 2 NR 2 R 3 is bonded to the carbon atom of either of X and Y, or an alkali metal salt thereof, in an amount sufficient to effect said treatment.
8. The composition according to claim 7 wherein said compound is in dosage unit form.
9. The composition according to claim 1 wherein said composition is in the form of a tablet or capsule.
10. The composition according to claim 7 wherein said compound that enhances the activity of norepinephrine and/or dopamine is bupropion and said anticonvulsant is zonisamide.
11. The composition according to claim 7 wherein said compound that enhances the activity of norepinephrine and/or dopamine is bupropion.